The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals’ ALYFTREK™ for treating cystic fibrosis in individuals aged six and older with specific gene mutations. This approval marks a ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...

The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in ...

Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

Vertex Pharmaceuticals raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments. Vertex Pharma raises annual revenue forecast on strong ...

South Africa's Competition Commission initiated an investigation into Vertex Pharmaceuticals for alleged excessive pricing ...

This blow comes amid mounting pressure from cheaper, authorized copies of Novo's and Eli Lilly's medications. Meanwhile, ...